The Senate Republicans’ bill to repeal and replace the Affordable Care Act would result in the loss of health insurance for 22 million Americans in 2026 relative to the number who would be insured under current law, according to the nonpartisan Congressional Budget Office’s report.
The Senate Republicans’ bill to repeal and replace the Affordable Care Act (ACA) would result in the loss of health insurance for 22 million Americans in 2026 relative to the number who would be insured under current law, according to the nonpartisan Congressional Budget Office’s (CBO) report. The CBO previously estimated that the House version of the bill, which passed in May, would result in 23 million Americans losing health insurance coverage. The report also found that, as soon as 2018, 15 million more people would be uninsured relative to current law. The legislation would decrease the federal deficit by $321 billion over 10 years.
Senate leaders today postponed a vote on the bill until after the July 4th congressional recess. With Democrats united against the legislation, there can be no more than 2 Republicans voting with Democrats against the motion to proceed. Currently, 4 Republicans have opposed the motion; 2 others have not yet declared opposition, but may also decide to oppose.
Among the key features of the Better Care Reconciliation Act of 2017 (BCRA) are the following:
The BCRA is opposed by many healthcare groups, including the American Medical Association and every major hospital association. Hospitals focused their concerns on proposed cuts to Medicaid, which provides health insurance to 73 million low-income and disabled Americans who would otherwise have no health insurance when they require hospitalization. The National Rural Health Association noted that small hospitals and rural hospitals are already struggling to “keep their lights on” and rely on Medicaid payments to survive.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.